{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Kaplan and Meier product limit methods will be used to estimate the DOR with 95% confidence intervals.","groups":[{"description":"Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)","id":"OG000","title":"Tivantinib Treatment"}],"populationDescription":"No participants responded to the therapy and no analyses were done","reportingStatus":"POSTED","timeFrame":"From first observation of partial response to the time of disease progression, assessed up to 30 days","title":"Duration of Response","type":"OTHER_PRE_SPECIFIED"}